SecBot SecBot

VERA drug pipeline

Vera Therapeutics, Inc. · 1 rated drug
$28.10
−3.2% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±5.7%
1-day, median of 8 events
IV rank
No data
No current options data
Rated drugs
1
1 bullish
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseApproved (Accelerated Approval)
Time to marketAlready FDA-approved (July 7, 2026) — launched commercially; confirmatory full-approval data expected Q3 2026

TRUTAKNA atacicept-vymj Updated Jul 7

What to watch

The FDA approval is already priced in (modest +6.8% move on the day). The real binary catalysts ahead are the ORIGIN 3 eGFR confirmatory data (Q3 2026) and commercial launch execution metrics. Watch pricing/reimbursement decisions, early prescription uptake, and whether the confirmatory eGFR data supports full approval. The IgAN market is getting crowded (Tarpeyo, Filspari, Fabhalta, Vanrafia, Voyxact), so differentiation on convenience (at-home autoinjector) and upstream mechanism (dual BAFF/APRIL) will determine commercial success.

Bull case
  • First approved dual BAFF/APRIL inhibitor for IgAN, disease-modifying mechanism targeting upstream root cause of the disease, not just symptoms
  • Compelling Phase 3 ORIGIN 3 data: 46% proteinuria reduction at 36 weeks (42% vs placebo, p<0.0001) with durability out to 96 weeks in Phase 2b, described by Evercore analysts as feeling like a 'functional cure'
  • Self-administered at-home once-weekly autoinjector offers significant convenience advantage over many competitors
Bear case
  • Crowded and increasingly competitive IgAN market, existing approved drugs include Tarpeyo/Calliditas, Filspari/Travere, Fabhalta/Novartis, Vanrafia/Novartis (Apr 2025), and Voyxact/Otsuka (2025), all competing for the same patient population
  • Accelerated approval requires confirmatory eGFR data (Q3 2026), if eGFR preservation is not statistically significant, full approval could be jeopardized
  • Historical atacicept safety concerns: 150 mg dose arm in a lupus trial was discontinued early due to two deaths (though IgAN trial at same dose showed favorable safety)

Past FDA events & how the stock moved

8 events
DateDrugEvent1 day5 days
Nov 3, 2026TRUTAKNABLA filed+5.7%—
Aug 10, 2026TRUTAKNAAccelerated approval−7.9%−3.8%
Jul 7, 2026TRUTAKNAApproval+5.7%+7.5%
Jul 7, 2026TRUTAKNAPDUFA decision+5.7%+7.5%
Jul 7, 2026TRUTAKNAPriority review+5.7%+7.5%
Jul 7, 2026TRUTAKNABLA filed+5.7%+7.5%
May 7, 2026TRUTAKNAPriority review−1.1%+8.1%
Feb 26, 2026TRUTAKNAPriority review−2.1%−6.8%

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
TRUTAKNAMonthly Dosing of Atacicept in IgANPhase 2Active not recruiting90Sep 2026